PHASE Scientific Americas Blog
REVIEW TRENDING INDUSTRY, BUSINESS & GOVERNMENT INFORMATION
THE DIAGNOSTIC PARTNER: ADDRESSING THE EQUITY IMPLICATIONS OF HEALTH DIAGNOSTICS
February 27, 2023
Achieving health equity, in which everyone has a fair and just opportunity to attain their highest level of health, requires ongoing efforts to address historical and contemporary injustices, overcome barriers to healthcare access, […]
THE DIAGNOSTIC PARTNER: EXPANDING THE USE OF TEST-TO-TREAT IN THE POST-PANDEMIC WORLD
February 20, 2023
The federal COVID-19 Test-to-Treat program launched in March 2022 but the test-to-treat response to infectious disease isn’t new. It does need renewal, however.
Test-to-treat describes an early intervention approach to infectious disease in which […]
OMICRON VARIANT UPDATE
November 21, 2022
Phase Scientific continuously monitors emerging variants of the virus that causes COVID-19 and how their mutations may impact the performance of the INDICAID® COVID-19 Rapid Antigen Test.
An independent evaluation by the National […]
Targeting COVID-19 Absenteeism with Test to Treat Approach
By Doug Field, Chief Revenue Officer, PHASE Scientific Americas
While the recent surges of current COVID-19 variants are not driving high levels of hospitalization and death, the persistent, circulating virus continues to affect employees and spike […]
How Often Can I Be Infected with the Coronavirus?
July 15, 2022 (reprint of article by Apoorva Mandavilli, NY Times)
A virus that shows no signs of disappearing, variants that are adept at dodging the body’s defenses, and waves of infections two, […]
This Covid Wave Might Be The Start Of Our ‘New Normal’
June 11, 2022 (reprint of article byElizabeth Yuko, Special to CNBC – Make It)
Packed indoor events and fully booked flights where masks are few and far between suggest that the pandemic is […]
INDICAID’S Omicron Variant Update
INDICAID’s Omicron BA.2 Variant Update
April 04, 2022
Phase Scientific continuously monitors emerging variants of the virus that causes COVID-19 and how their mutations may impact the performance of the INDICAID® COVID-19 Rapid Antigen test. A sub-variant […]
Facing the “Stealth Omicron” Sub-variant’s Dominance Head-On
No New Surges Means Good Preventive Care
Despite its pervasiveness and spikes in Asia and Europe, the Covid-19 Omicron BA.2—dubbed the Stealth Omicron by the World Health Organization (WHO)—has appeared to have lost its choke-hold on […]
A Premium At-Home COVID-19 Rapid Antigen Testing Product Hits U.S. Retail Stores
PHASE Scientific’s INDICAID® Covid-19 Rapid Antigen Test Obtains FDA Emergency Use Authorization (EUA) for Over-the-Counter (OTC), Asymptomatic, Non-Prescription Use
March 16, 2022 : The biotech conglomerate, PHASE Scientific USA, announced the FDA’s EUA green-light to launch […]
AMA Updated Coding Guidelines
Best Coding Practices for Coverage of Covid-19 Testing, Monitoring, and Telehealth
Late last year, the American Medical Association (AMA) released an updated version of its document, ‘Special coding advice during COVID-19 public health emergency.’
FAQS About Families First Coronavirus Response Act
And Coronavirus Aid, Relief, And Economic Security Act Implementation Part 52
February 4, 2022 : Set out below are Frequently Asked Questions (FAQs) regarding implementation of the Families First Coronavirus Response Act (FFCRA) and the Coronavirus […]
Pandemic to Endemic
As cases of Covid-19 become increasingly mild and isolated, we have hope of a ‘new normal’ through continued vaccinations and testing
Starting February 1, 2022, Denmark has made the bold decision to lift most pandemic restrictions […]
Looking for more to read…
How about reading our corporate News?